These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 12527930)
1. High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism. Gross E; Seck K; Neubauer S; Mayr J; Hellebrand H; Ratanaphan A; Lutz V; Stockinger H; Kiechle M Int J Oncol; 2003 Feb; 22(2):325-32. PubMed ID: 12527930 [TBL] [Abstract][Full Text] [Related]
2. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Ezzeldin H; Okamoto Y; Johnson MR; Diasio RB Anal Biochem; 2002 Jul; 306(1):63-73. PubMed ID: 12069415 [TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography. Fischer J; Schwab M; Eichelbaum M; Zanger UM Genet Test; 2003; 7(2):97-105. PubMed ID: 12885330 [TBL] [Abstract][Full Text] [Related]
4. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976 [TBL] [Abstract][Full Text] [Related]
5. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD. Saif MW Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601 [TBL] [Abstract][Full Text] [Related]
7. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing. van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938 [TBL] [Abstract][Full Text] [Related]
8. A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant. De Falco V; Natalicchio MI; Napolitano S; Coppola N; Conzo G; Martinelli E; Zanaletti N; Vitale P; Giunta EF; Vietri MT; Vitiello PP; Ciardiello D; Marinaccio A; De Vita F; Ciardiello F; Troiani T Medicine (Baltimore); 2019 May; 98(21):e15759. PubMed ID: 31124962 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Seck K; Riemer S; Kates R; Ullrich T; Lutz V; Harbeck N; Schmitt M; Kiechle M; Diasio R; Gross E Clin Cancer Res; 2005 Aug; 11(16):5886-92. PubMed ID: 16115930 [TBL] [Abstract][Full Text] [Related]
10. [Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance]. Gross E; Seck K; Kiechle M Zentralbl Gynakol; 2002 Dec; 124(12):574-9. PubMed ID: 12822071 [TBL] [Abstract][Full Text] [Related]
11. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Collie-Duguid ES; Etienne MC; Milano G; McLeod HL Pharmacogenetics; 2000 Apr; 10(3):217-23. PubMed ID: 10803677 [TBL] [Abstract][Full Text] [Related]
12. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Amstutz U; Froehlich TK; Largiadèr CR Pharmacogenomics; 2011 Sep; 12(9):1321-36. PubMed ID: 21919607 [TBL] [Abstract][Full Text] [Related]
14. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223 [TBL] [Abstract][Full Text] [Related]
15. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084 [TBL] [Abstract][Full Text] [Related]
16. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil. Yamaguchi K; Arai Y; Kanda Y; Akagi K Jpn J Cancer Res; 2001 Mar; 92(3):337-42. PubMed ID: 11267945 [TBL] [Abstract][Full Text] [Related]
17. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. Wei X; McLeod HL; McMurrough J; Gonzalez FJ; Fernandez-Salguero P J Clin Invest; 1996 Aug; 98(3):610-5. PubMed ID: 8698850 [TBL] [Abstract][Full Text] [Related]
18. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Omura K Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836 [TBL] [Abstract][Full Text] [Related]
19. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil]. Ostapowicz A; Dołegowska B Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991 [TBL] [Abstract][Full Text] [Related]
20. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population. Ben Fredj R; Gross E; Chouchen L; B'Chir F; Ben Ahmed S; Neubauer S; Kiechle M; Saguem S C R Biol; 2007 Oct; 330(10):764-9. PubMed ID: 17905396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]